CreatorsPublishersAdvertisers
View more in
Cancer

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer

patientdaily.com
 2021-09-20

Cover picture for the articleMirati Therapeutics, Inc. issued the following announcement on Sep. 9. Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily...

patientdaily.com

Comments / 0

Comments / 0